Great Novel Therapeutics Biotech & Medicals EBIT

Great Novel Therapeutics Biotech & Medicals (7427.TWO) currently reports a EBIT of $-200M as of June 2026. That compares with $-170M in the prior-year period — down 18.8% year over year. That is below the Healthcare sector average of $130B. Use the charts on this page to explore Great Novel Therapeutics Biotech & Medicals's EBIT history and peer comparisons.

Great Novel Therapeutics Biotech & Medicals's EBIT decreased from $-170M to $-200M — a 18.8% year-over-year decrease (period ending June 2026). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.

Great Novel Therapeutics Biotech & Medicals's EBIT of $-200M is lower than the Healthcare sector average of $130B. That is roughly 100.2% below the sector mean. A reading lower peers can reflect different growth expectations, capital structure, or profitability — so it is worth checking the peer comparison chart before drawing conclusions.

Great Novel Therapeutics Biotech & Medicals reported $-200M in EBIT as of June 2026. That compares with $-170M in the prior-year period — down 18.8% year over year. Absolute dollar amounts are most useful when compared with prior periods, peers, and related line items such as revenue, assets, or liabilities on Stockcircle.

Start with the current EBIT of $-200M, then check the historical chart for trend and the peer comparison chart for relative positioning. The Healthcare average is $130B. From there, open related valuation or income-statement pages for Great Novel Therapeutics Biotech & Medicals, and consider following 7427.TWO for alerts when major investors trade the stock.